Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …

Over the past decade, the amount of research and the number of publications on
associations between circulating small and long non-coding RNAs (ncRNAs) and cancer …

New research has indicated that long non-coding RNAs (lncRNAs) play critical roles in a
broad range of biological processes, including the pathogenesis of many complex human …

Resistance against conventional chemotherapeutic agents is one of the main reasons for
tumor relapse and poor clinical outcomes in cancer patients. Various mechanisms are …

Long non-coding RNAs (lncRNAs) are important biological mediators that regulate
numerous cellular processes. New experimental evidence suggests that lncRNAs play …

H19 long non-coding RNA (lncRNA) has many functions in cancer. Some studies have
reported that H19 acts as an oncogene and is involved in cancer progression by activating …

Primary liver cancer is the sixth most common cancer and the third most common cause of
cancer-related deaths worldwide. Hepatocellular carcinoma (HCC) is a major histologic type …

First-generation EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib have significant
activity in NSCLC patients with activating EGFR mutations. However, EGFR-TKI resistance …

With advances in genome and transcriptome research technology, the function and
mechanism of lncRNAs in physiological and pathological states have been gradually …

Long non-coding RNAs (lncRNAs) represent a major fraction of the transcriptome in
multicellular organisms. Although a handful of well-studied lncRNAs are broadly recognized …